Key facts
- This page summarizes Christopher Downs's Form 4 filing for CNS Pharmaceuticals, Inc. (CNSP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 14 Mar 2022, 09:40.
Christopher Downs - 11 Mar 2022 Form 4 Insider Report for CNS Pharmaceuticals, Inc. (CNSP)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CNSP
- Reported as of
- 11 Mar 2022
- Net transaction value
- +$10,230
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2022, 09:40:12 UTC
- Prior SEC filing
- 11 Feb 2022
- Next SEC filing
- 29 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christopher Downs
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Downs filed Form 4 for CNS Pharmaceuticals, Inc. (CNSP) on 14 Mar 2022.
Change
- Previous filing in this sequence was filed on 11 Feb 2022.
- Current net transaction value: +$10,230.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CNSP
transaction
Common Stock
Award
- Transaction value
- $10,230
- Shares
- +33,000
- Change %
- +22%
- Price
- $0.3100
- Shares after
- 184,500
- Date
- 11 Mar 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.